BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 27769906)

  • 1. Transthyretin Cardiac Amyloidosis in Older Americans.
    Brunjes DL; Castano A; Clemons A; Rubin J; Maurer MS
    J Card Fail; 2016 Dec; 22(12):996-1003. PubMed ID: 27769906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging.
    Narotsky DL; Castano A; Weinsaft JW; Bokhari S; Maurer MS
    Can J Cardiol; 2016 Sep; 32(9):1166.e1-1166.e10. PubMed ID: 27568874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The quintessential form of diastolic heart failure in older adults: Wild type transthyretin cardiac amyloidosis.
    Driggin E; Maurer MS
    Clin Cardiol; 2020 Feb; 43(2):171-178. PubMed ID: 31825134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy.
    Galant NJ; Westermark P; Higaki JN; Chakrabartty A
    Clin Sci (Lond); 2017 Mar; 131(5):395-409. PubMed ID: 28213611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First nationwide survey on systemic wild-type ATTR amyloidosis in Japan.
    Sekijima Y; Yazaki M; Ueda M; Koike H; Yamada M; Ando Y
    Amyloid; 2018 Mar; 25(1):8-10. PubMed ID: 29182024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
    Rubin J; Maurer MS
    Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope.
    González-López E; López-Sainz Á; Garcia-Pavia P
    Rev Esp Cardiol (Engl Ed); 2017 Nov; 70(11):991-1004. PubMed ID: 28870641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac amyloidosis: updates in diagnosis and management.
    Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
    Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid myopathy: expanding the clinical spectrum of transthyretin amyloidosis-case report and literature review.
    Ungericht M; Wanschitz J; Kroiss AS; Röcken C; Schuetz T; Messner M; Zaruba MM; Loescher WN; Poelzl G
    J Nucl Cardiol; 2023 Aug; 30(4):1420-1426. PubMed ID: 35581484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive detection and differentiation of cardiac amyloidosis using
    Takasone K; Katoh N; Takahashi Y; Abe R; Ezawa N; Yoshinaga T; Yanagisawa S; Yazaki M; Oguchi K; Koyama J; Sekijima Y
    Amyloid; 2020 Dec; 27(4):266-274. PubMed ID: 32722948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.
    Rigopoulos AG; Ali M; Abate E; Torky AR; Matiakis M; Mammadov M; Melnyk H; Vogt A; de Vecchis R; Bigalke B; Wohlgemuth W; Mavrogeni S; Noutsias M
    Heart Fail Rev; 2019 Jul; 24(4):521-533. PubMed ID: 30790171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transthyretin amyloid cardiomyopathy.
    Garcia-Pavia P; Domínguez F; Gonzalez-Lopez E
    Med Clin (Barc); 2021 Feb; 156(3):126-134. PubMed ID: 33138983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.
    Lyng CS; Gude E; Hodt A; Knudsen EC
    Scand Cardiovasc J; 2023 Dec; 57(1):2174269. PubMed ID: 36734834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology and clinical manifestations of cardiac amyloidosis.
    Bajwa F; O'Connor R; Ananthasubramaniam K
    Heart Fail Rev; 2022 Sep; 27(5):1471-1484. PubMed ID: 34694575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac Amyloidosis Imaging, Part 3: Interpretation, Diagnosis, and Treatment.
    Jerome S; Farrell MB; Warren J; Embry-Dierson M; Schockling EJ
    J Nucl Med Technol; 2023 Jun; 51(2):102-116. PubMed ID: 37268322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid cardiomyopathy.
    Kristen AV
    Herz; 2020 May; 45(3):267-271. PubMed ID: 32107564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiac amyloidosis: State of art in 2022].
    Oghina S; Delbarre MA; Poullot E; Belhadj K; Fanen P; Damy T
    Rev Med Interne; 2022 Sep; 43(9):537-544. PubMed ID: 35870985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
    Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.